Xilio Therapeutics, Inc. · NASDAQ:XLO
Xilio Therapeutics, Inc. shareholders
As of Jun 30, 2026, 24 institutions reported holding Xilio Therapeutics, Inc., 47.7% of its shares. Largest: Bain Capital Life Sciences Investors, LLC, Orbimed Advisors LLC and Frazier Life Sciences Management, L.P. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of Xilio Therapeutics, Inc. | Change | Filed |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664K | 11.5% | no change | Aug 14, 2026 |
| Orbimed Advisors LLC | 592K | 10.2% | new | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 423K | 7.3% | no change | Aug 14, 2026 |
| Stonepine Capital Management, LLC | 226K | 3.9% | +162K | Aug 17, 2026 |
| Vanguard | 201K | 3.5% | +48,976 | Aug 13, 2026 |
| Sio Capital Management, LLC | 152K | 2.6% | no change | Aug 14, 2026 |
| Adage Capital Partners Gp, L.L.C. | 112K | 1.9% | new | Aug 14, 2026 |
| Merck & Co., Inc. | 106K | 1.8% | no change | Aug 7, 2026 |
| Renaissance Technologies | 64,153 | 1.1% | +14,587 | Aug 13, 2026 |
| Morgan Stanley | 56,954 | 0.98% | −539 | Aug 13, 2026 |